Wi go tɔk bɔt dis siriɔs blɔd kansa, Acute Myeloid Leukemia (AML)?

Yu gɛt kol we nɔ de go afta sɔm dez? Ɔ yu jɔs de fil taya ɛn yu taya? Sɔntɛnde, smɔl smɔl tin dɛn lɛk dis kin de ayd big tin. Tide wi go tɔk bɔt wan sik we siriɔs smɔl, bɔt i rili impɔtant fɔ no bɔt. Dat na akyu mayloid lukimiya, ɔ AML fɔ shɔt.

Wetin na AML?

Fɔ tɔk am simpul wan, Acute Myeloid Leukemia (AML) na wan kayn kansa we kin afɛkt yu bon mɛrɔ ɛn blɔd. Na sik we nɔ kin apin so ɔltɛm bɔt i kin rili bad. Bɔku tɛm, i kin kam bikɔs wan pan yu jin ɔ kromozom dɛn chenj. I kin kam pan pipul dɛm wae dɔn pas 60. Bɔt i kin afɛkt yɔŋ pipul dɛm ɛn pikin dɛm bak. AML na kansa we de prɛd kwik kwik wan ɛn we de mek pɔsin in layf de pan denja. Bɔt gud tin na dat, nyu tritmɛnt dɛn dɔn mek bɔku pipul dɛn ebul fɔ liv lɔng wit dis sik.

Difrɛn kayn AML dɛn de?

Yes, sɔm difrɛn sɔbtayp dɛn de fɔ AML. Ɛni wan pan dɛn kayn tin ya kin afɛkt di nɔmba fɔ di sɛl dɛn we de na yu blɔd. Bɔt ɛni kayn sik kin mek yu gɛt difrɛn sayn dɛn ɛn di we aw dɛn kin du tin difrɛn we we dɛn de gi yu tritmɛnt.

Dɔktɔ dɛn kin no dɛn smɔl kayn AML ya bay we dɛn kin chɛk di kansa sɛl dɛn ɔnda maykroskɔp. Dɛn kin luk bak fɔ chenj dɛn na yu kromozom dɛn ɛn chenj dɛn na sɔm jin dɛn we de kɔntrol di we aw di sɛl dɛn de gro.

Na sɔm pan di men sɔbtayp dɛm fɔ AML:

• Mayloid leukemia: Dis na di kayn AML we dɛn kin gɛt mɔ. I de divɛlɔp lɛk kansa na di sɛl dɛn we de mek nyutrofil, we na wan kayn wayt blɔd sɛl.
• Akyu monosaytik lukimiya (AML-M5): dis de divεlכp insay sεl dεm we de mek wan kayn wayt bכdi sεl we dεn kכl monosayt.
• Acute megakaryocytic leukemia (AMLK): Dis na kansa na di sɛl dɛm we de mek rɛd blɔd sɛl ɔ pletlɛt.
• Acute promyelocytic leukemia (APL): Insay dis, wan kayn wayt blɔd sɛl we nɔ machɔ we dɛn kɔl promyelocytes nɔ de divɛlɔp fayn ɛn i kin bi kansa sɛl.

Aw kɔmɔn tin fɔ AML?

AML na rili sik we nɔ kin bɔku. Na avrej, na lɛk 4 pan ɔl 100,000 big pipul dɛn kin gɛt dis sik ɛvri ia. Dɔn bak, dɛn ripɔt se ɛvri ia na lɛk 1,160 pikin dɛn kin gɛt AML.

Wetin na di sayn dɛm fɔ AML?

Na di fɔs tɛm, di AML simptom kin fil lɛk yu gɛt bad kol ɔr flu we dɔn de fɔ sɔm dez. Bɔt AML na kansa we rili agresiv. Dat min se, .I nɔ go te igen yu go bigin fɔ gɛt nyu sayn dɛn we de sho se yu gɛt dis sik. Leta, yu kin notis sɔm sayn dɛn lɛk:

• Fɔ fil lɛk se yu de tɔn diziz ɔltɛm.
• Tin dɛn lɛk fɔ brus izi wan, fɔ blɔd na yu nos ɔltɛm, ɛn fɔ blɔd na yu gɔm we yu de brus yu tit.
• Fɔ fil se yu taya we yu nɔ go ebul fɔ bia.
• Fɔ fil kol.
• Fiva.
• Nayt swet dɛn.
• Infεkshכn kin apin bכku tεm, כ infεkshכn we kin apin kin tek lכng tεm fכ hεl.
• Ɛd we de at.
• Di it nɔ de te.
• Fɔ bi tin fɔ no rizin.
• Pale skin.
• I nɔ izi fɔ blo (dyspnea).
• Di limf no dɛm we dɔn swel.
• Fɔ fil se yu wik.
• Pen na di bon, bak, ɔ bɛlɛ.
• Smɔl rɛd spat dɛn na di skin (petechiae).
• Wund dɛn kin tek tɛm fɔ wɛl.

Wetin na di tin dɛn we kin mek pɔsin gɛt AML?

Di masta sabi pipul dɛn stil nɔ no bɛtɛ bɛtɛ wan wetin kin mek pɔsin gɛt AML. Bɔt dɛn no se di sik kin apin we sɔm jin ɔ kromozom dɛn na wi bɔdi chenj (mutate), we kin mek blɔd sɛl dɛn we nɔmal fɔm. Dɛn chenj ya we kin apin na di jɛnɛtiks kin inklud:

• Sɔntin dɔn afɛkt yu DNA insay yu layf.
• If yu gɛt wan jenɛtik disɔda wae de pas dɔŋ to jɛnɛreshɔn ɛn de mek yu gɛt mɔ risk fɔ gɛt AML.
• Na bikɔs sɔm pan di jin dɛn we de na yu mama ɛn papa dɛn sperm ɔ eg chenj.

Aw di chenj dɛn we de apin na di jɛnɛtiks kin mek pɔsin gɛt AML?

Fɔ ɔndastand aw dɛn jɛnɛtik chenj ya kin mek yu gɛt AML, i go fayn fɔ no smɔl bɔt yu bon mɛro ɛn blɔd sɛl dɛn. yu bon mכro na di sכft, sכft tisu we de na di sεntrכm fכ bכku pan yu bon dεm. I mek am wit:

• stεm sεl dεm de fכm. Dis na di sɛl dɛn we leta bi rɛd blɔd sɛl dɛn we de kɛr ɔksijɛn, wayt blɔd sɛl dɛn we de protɛkt pɔsin frɔm di sik, ɛn di pletlɛt dɛn we de ɛp fɔ mek di blɔd klɔt.

Nɔmal wan, yu bon mɛro kin wok lɛk wan fayn prodakshɔn layn, we kin mek jɔs di rayt blɔd sɛl ɛn pletlɛt fɔ yu bɔdi. Bɔt pan pɔsin we gɛt AML, di bon mɛro kin bigin fɔ mek abnɔmal mayloid sɛl dɛn we dɛn kɔl mayloid blast ɔ myeloblast.

dis mayloid blast sεl dεm nכ de bihayv lεk nכmal bכdi sεl dεm. di nכmal sεl dεm kin gεt instrכkshכn frכm dεn jin dεm bכt usεn εn aw fast dεn fכ divayd εn gro. We di sɛl dɛn ol, dɛn kin day fɔ mek ples fɔ nyu sɛl dɛn na di bon mɛro. bכt di mayloid blast sεl dεm nכ de fala dεn instrכkshכn ya. Dɛn de sheb we dɛn nɔ ebul fɔ kɔntrol dɛnsɛf ɛn dɛn nɔ de day. as di mayloid blast sεl dεm de kכntinyu fכ fulכp di bon mכro, nכ rum de fכ hεlty bכdi sεl dεm. Bikɔs rum nɔ de, di bon mɛro kin stɔp fɔ mek wɛlbɔdi blɔd sɛl dɛn. If yu nɔ gɛt nyu wɛlbɔdi blɔd sɛl, di bɔdi nɔ go gɛt di tin dɛn we i nid fɔ wok fayn fayn wan.

pan tap dat, as dεn mayloid blast sεl dεm ya de kכntinyu fכ sheb, dεn de kכmכt na di bon mכro εn go insay di bכdi. We dɛn dɔn rich na di blɔd, dɛn mayloid sɛl ya kin travul go na ɔda pat dɛn na di bɔdi, lɛk yu sɛntral nɛvɔ sistɛm, yu bren, ɛn yu spɛnal kɔd.

Wetin na di tin dɛm wae kin mek pɔrsin gɛt AML?

Pan ɔl we masta sabi pipul dɛn nɔ no bɛtɛ bɛtɛ wan wetin kin mek yu gɛt di jenɛtik muteshon we kin mek yu gɛt AML, dɛn no bɔt sɔm tin dɛn (risk factors) we kin mek yu gɛt mɔ risk fɔ gɛt di sik. (We wi tink bɔt tin dɛn we kin mek yu gɛt dis sik, i impɔtant fɔ mɛmba se if yu gɛt dis sik nɔ min se yu go gɛt di sik. ) Di tin dɛn we kin mek yu gɛt dis sik na:

• Ej: Na lɛk af pan di pipul dɛn we gɛt AML kin ol 65 ia ɔ pas dat we dɛn no se dɛn gɛt am. Bɔt lɛk aw wi bin dɔn tɔk, AML kin apin mɔ pan big pipul dɛn, bɔt i kin apin bak pan pikin dɛn.
• Smok: Dis inklud fɔ inhal sɛkɔnhand smok.
• Tritmɛnt fɔ kansa: Tin dɛn lɛk kemotɛrapi ɛn redyushɔn tɛrapi.
• Fɔ lɔng tɛm we pɔsin kin gɛt sɔm kemikal dɛn we kin mek pɔsin gɛt kansa: Sɔm ɛgzampul dɛn na tin dɛn lɛk bɛnzin ɛn fɔmaldehayd.
• If yu gɛt bɔku bɔku raytin frɔm nyuklia riaktɔ aksidɛnt ɔ atɔmik bɔm.
• Sɔm sik dɛn we dɛn kin gɛt frɔm dɛn mama ɛn papa.
• Ɔda prɔblɛm dɛn we kin mek pɔsin gɛt bon mɛrɔ.

Us sik dɛn we kin mek pɔsin gɛt AML?

Risach pipul dεm dכn fכnshכn se sכm jεnεtik mכtεshכn dεm we dεn gεt inhεrit de mek di risk fכ gεt AML. Sɔm pan dɛn tin ya na:

• Sindrom we gɛt di sik we dɛn kɔl Down syndrome
• Ataxia telangiectasia we pɔsin kin gɛt
• Li-Fraumeni sindrom we gɛt di sik
• Di sik we dɛn kɔl Klinefelter syndrome
• Fankɔni anemia
• Wiskott-Aldrich syndrome - Dis kin afekt di pletlet prodakshכn.
• Blɔm sindrom we gɛt di sik
• Famili Plɛtlɛt Disɔda sindrom - Dis na sik bak we gɛt fɔ du wit pletlɛt.

Us bon mɛrɔ sik dɛn we de mek pɔsin gɛt AML?

Sɔm pipul dɛm wae gɛt mayloproliferative neoplasm, ɔ myeloproliferative disorder, kin gɛt akyu mayloid lukemia. (Myelo min bon mכro. Proliferative min fכ gro tu mכch.) Pipul dεm we gεt dεn kכndyushכn dεm ya kin gεt hכy risk fכ gεt AML bak:

• Polisaytemia vera
• Maylofibrosis we dɛn kɔl myelofibrosis
• Trombosaytɔsis we de mek pɔsin gɛt sik
• Maylodysplastik sindrom we gɛt di sik
• Aplastik anemia we dɛn kin gɛt

Wetin na di prɔblɛm dɛn we kin kam wit AML?

We i bigin, akyu mayloid lukimiya kin afɛkt di nɔmba fɔ di wɛlbɔdi rɛd blɔd sɛl dɛn, wayt blɔd sɛl dɛn, ɛn di pletlɛt dɛn na yu bɔdi. If yu nɔ gɛt bɛtɛ wɛlbɔdi blɔd sɛl ɛn pletlɛt, yu kin gɛt tin dɛn lɛk:

• Anemia - dat min se blɔd nɔ de.
• Trombocytopenia - Dis min se di pletlet dεm nכ de.
• Pancytopenia - dis min se כl kayn bכdi sεl dεm εn di pletlεt dεm de dכn.

Aw dɛn kin no se pɔsin gɛt AML? (Diagnosis) .

Dɔktɔ dɛn kin yuz bɔku tɛst dɛn fɔ no if pɔsin gɛt AML, ɛn dɛn kin yuz dɛn jenɛtik tɛst fɔ no di rayt kayn AML. Bɔku tɛm, di fɔs tin we yu fɔ du na fɔ chɛk yu bɔdi. Dis kin min fɔ chɛk if yu gɛt brus, blɔd, ɛn infekshɔn. Dɛn kin chɛk bak fɔ si if di ɔgan dɛn lɛk di liva, di splin, ɛn di limf no dɛn swel.

Us tɛst dɛn kin yuz fɔ no if pɔsin gɛt AML?

Yu kin nid fɔ du wan ɔ mɔ pan dɛn tɛst ya:

• Kɔmplit blɔd kɔnt (CBC) .
• Pεrifεral bכdi smεl - Dis involv fכ tek bכdi sεmpl εn luk am כnda maykroskכp.
• bon mכro bayopsi - insay dis, dεn de tek sכm sכm sεmpl fכ bon mכro εn egzamin am.
• sכmtεm dεn kin du dis fכ chεk fכ kεnsar sεl dεm na di wata we de rawnd di spεnal kכd.

Wetin na di jenɛtik tɛst dɛn we dɛn kin yuz fɔ no if pɔsin gɛt AML?

Di mɛdikal patɔlɔjis dɛn kin du jenɛtik tɛst fɔ no di rayt kayn AML. dεn de luk fכ chenj (mכtεshכn) dεm na sכm kromozom כ jin dεm. We dɛn dɔn no di kayn AML, i kin izi fɔ dɔktɔ dɛn fɔ disayd us tritmɛnt dɛn go mɔs mɛn di AML. Sɔm pan di patikyula tɛst dɛn we dɛn kin du fɔ dis na:

• Immunohistochemistry: insay dis, dεn de stεn di sεl dεm εn egzamin dεm כnda maykroskכp. di we aw dεn de stεyn difrεn difrεnt dipכnt pan di kεmikכl dεm we de insay di sεl dεm.
• Flɔ saytometri fɔ yuz.
• Karyotayp tɛst.
• Fluorescence-in-situ-hybridization (FISH): dis kin no di chenj dεm we de apin na di kromozom dεm.

Wetin na di tritmɛnt dɛm fɔ AML?

Di tritmɛnt opshɔn dɛm na kemotɛrapi, targeted tɛrapi (inklud monoklɔnal antibodi tɛrapi), ɔ allogeneic stem cell transplantation. Di sem tritmɛnt dɛn de fɔ big pipul ɛn pikin dɛn. Di ɔltimat gol fɔ tritmɛnt na fɔ rich kɔmplit rɛmishɔn fɔ AML.Insay AML, ‘kɔmplit mɛn’ min se yu blɔd kɔnt nɔmal pan tɛst. I min bak se dɔktɔ dɛn nɔ kin si ɛni kansa sɛl we dɛn luk wan sɛmpul pan yu bon mɛro ɔnda maykroskɔp.

Kimotɛrapi fɔ AML

Tri men pat dεm de fכ di kεmothεrapi fכ AML - indukshכn, kכnsolidεshכn, εn mεntenans.

Rimishɔn indukshɔn tɛrapi

Dis na di fɔs tin we yu fɔ du fɔ pul AML kɔmɔt kpatakpata. Bɔrku tɛm, di tritmɛnt kin te fɔ sɔm dez. Sɔm pipul dɛn kin nid tu ɔ mɔ rawnd fɔ dis fɔs tritmɛnt fɔ pul AML kɔmɔt kpatakpata. Dɔktɔ dɛn kin yuz dɛn kemotɛrapi mɛrɛsin ya fɔ dis fɔs tritmɛnt:

• Saytarabin (Saytosar-U®) we dɛn kɔl .
• Daunorubisin (Sɛrubidin®) .
• Idarubisin (Idamycin®) we dɛn kɔl Idarubisin.
• Azasitidin (Vidaza®) we dɛn kɔl .
• Desitabin (Dacogen®) we dɛn kɔl di .
• Glasdegib (Daurismo®) we de wok fɔ di kɔmni.
• Venetoklaks (Vɛnklɛksta®, Vɛnkliksto®) .

Masta sabi bukman dɛn se dɛn fɔs tritmɛnt ya:

• Mɔ pas 60% pan di pikin ɛn yɔŋ pipul dɛn kin wɛl.
• Na lɛk 75% pan di big pipul dɛm we ol 60 ia ɛn ɔnda de wɛl.
• Na lɛk 50% pan pipul dɛm wae dɔn pas 60 ia kin wɛl.

Kɔnsolidɛshɔn tɛrapi

Dɛn kin yuz kɔnsolidɛshɔn tɛrapi fɔ kil ɛni kansa sɛl we lɛf. Dis kin ridyus di risk fɔ mek di kansa kam bak (we kin kam bak). Dɛn kin gi bɔku pipul dɛn ay doz saytarabin (Ara-C) ɔ HiDAC fɔ fayv dez ɛvri mɔnt fɔ tri to 4 mɔnt.

Mentɛnans tɛrapi

Bɔku tɛm, dɛn kin mɛn AML wit kɔnsolidɛshɔn tɛrapi. Bɔt sɔm tɛm dɛn de, dɔktɔ dɛn kin tɛl yu fɔ kɔntinyu fɔ tek kemotɛrapi we yu nɔ tek bɔku mɔni. Di mentenɛns tritmɛnt kin kɔntinyu fɔ sɔm mɔnt ɔ ia. Di mɛrɛsin dɛn we dɛn kin yuz fɔ mɛn di mɛrɛsin dɛn we dɛn kin yuz fɔ mɛn pipul dɛn kin gɛt:

• Azasitidin (Vidaza®) we dɛn kɔl .
• Desitabin (Dacogen®) we dɛn kɔl di .
• Midostaurin (Rydapt®) we dɛn kɔl midostaurin (Rydapt®) .

Targeted therapy

As di nem sho, dis tritmεnt de tכk bכt spεshal jεnεtik mכtεshכn dεm na di kεnsar sεl dεm. We dɛn de tɔch dɛn muteshon ya, di kansa sɛl dɛn kin stɔp fɔ gro. Monoklonal antibodi tεrapi na wan kayn tεrapi we dεn de tכk bכt. Dɔktɔ dɛn kin yuz di tritmɛnt dɛn we dɛn dɔn tɔk bɔt fɔ trit AML we nɔ dɔn ansa to kemotɛrapi ɔ we dɔn kam bak:

• Dɔktɔ dɛn kin yuz di kemotɛrapi drɔgs Midostaurin (Rydapt®) ɔ Gilteritinib (Xospata®) fɔ trit AML pasɛnt dɛn we gɛt di FTL3 jin muteshɔn. dis mכtεshכn de fכn pan 25% to 30% pan pipul dεm we gεt AML.
• Dɛn kin yuz Enasidenib (IDHIFA®) ɔ Ivosidenib (Tibsovo®) fɔ trit pipul dɛn we gɛt AML bikɔs ɔf wan muteshon na dɛn X jin.

Allojenik stεm sεl transplant

wan allojenik stεm sεl transplant de yuz stεm sεl dεm frכm wan dכna we rilet כ ​​we nכ rilet. dכkta dεm kin gεt dεn stεm sεl dεm ya frכm bon mכro, pεrifεral blכd, כ kכd blכd (blכd we dεn kכlekt frכm di כmbilikal kכd afta dεn bכn am).

Tritmɛnt kɔmplikɛshɔn ɔ sayd ɛfɛkt

Klose to ɔl di tritmɛnt dɛm fɔ kansa gɛt sayd ɛfɛkt. insay AML, stεm sεl transplant de gεt di mכst siriכs sayd ifekt dεm. Kimotɛrapi kin mek yu gɛt wan sik we dɛn kɔl myelosuppression, we min se yu bɔdi kin lɔs di nɔmal nɔmba fɔ di blɔd sɛl ɛn pletlɛt dɛn. Di sayd ɛfɛkt dɛm fɔ di tritmɛnt dɛm wae dɛn kin gɛt kin difrɛn difrɛn wan fɔ di mɛrɛsin wae dɛn kin yuse.

Fɔ ɔndastand di sayd ɛfɛkt dɛn impɔtant fɔ no aw di tritmɛnt fɔ kansa go afɛkt yu ɛvride layf. Yu dɔktɔ na di bɛst pɔsin fɔ no bɔt di patikyula sayd ɛfɛkt dɛn we yu tritmɛnt gɛt. Sɔm pipul kin bɛnifit frɔm palliativ kia fɔ ɛp fɔ kɔntrol di sayd ɛfɛkt dɛm.

Yu tink se dɛn kin mɛn AML ɔltogɛda?

naw, allogeneic stεm sεl transplant na di כnli we fכ kכmplit kכl akyu mayloid lukimiya. Dipen pan yu kɔndishɔn, yu dɔktɔ kin se yu fɔ transplant stem sɛl as yu fɔs AML tritmɛnt. Ɔ, if yu AML kam bak insay 12 mɔnt, dɛn kin se dɛn fɔ gi yu dis tritmɛnt. Bɔt i sɔri fɔ no se nɔto ɔlman fit fɔ gɛt stem sɛl transplant.

Wetin na di prɔgnosis fɔ AML?

We wi de tɔk bɔt di prɔgnosis fɔ akyu mayloid lukimiya, tu aspek dɛn de. Wan na fɔ rɛmishɔn kɔmplit wan. di כda wan na rikarεshכn, we na we AML de divεlכp bak.

• כlsay, dεn εstimat se bitwin 50% εn 80% pan di pipul dεm we gεt akyu mayloid lukimiya go mek ful rεkכvεshכn afta tritmεnt. Pikin ɛn pipul dɛn we nɔ rich 60 ia yet kin mek dɛn wɛl ful wan. Dis wɛl bɔdi kin te fɔ sɔm mɔnt ɔr ia.
• Na lɛk 50% pan di pipul dɛm wae kin wɛl ɔl go gɛt AML bak. If dis apin, dɔktɔ dɛn kin se dɛn fɔ tek ɔda kemotɛrapi ɔ fɔ transplant stem sɛl. Dɛn kin tɔk bak se yu fɔ tek pat pan wan klinik trial.

If yu ɔ yu pikin gɛt AML, aks yu dɔktɔ bɔt wetin yu go ɛkspɛkt.

Wetin na di rεt we AML pasεn dεm de liv?

Akyu mayloid lukimiya na wan kɔmpleks sik. Bikɔs sɔm sɔbtayp dɛn de fɔ AML, i nɔ kin izi fɔ gi ɛksaktɔl prɔgnosis.

Fɔ ɛgzampul, di fayv ia we pikin dɛn we nɔ rich 15 ia yet kin liv na 67%. Bɔt sɔm stɔdi dɛn sho se di fayv ia sɔvayv rɛt fɔ pikin dɛn we gɛt di sɔbtayp APL pas 80%. Di ej bak kin ɛp fɔ du sɔntin. Na avrej, 30% pan di big pipul dɛm we gɛt AML kin liv fayv ia afta dɛn dɔn no se dɛn gɛt am. Mɛmba se, AML kin kam pan pipul dɛm wae ol 60 ia ɔr pas dat, ɛn wae kin gɛt ɔda wɛl bɔdi prɔblɛm dɛm bak.

I impɔtant fɔ mɛmba se dɛn sɔvayv rɛt ya de sho di ɛkspiriɛns we big grup dɛn pan pipul dɛn we gɛt AML gɛt. Dis data inklud di sɔvayv rɛt frɔm 2012 to 2018, ɛn naw nyu, mɔ ifɛktiv tritmɛnt dɛn de fɔ AML.

Bɔrku tin kin afɛkt aw lɔng yu go liv wit akyu mayloid lukimiya. Dis min se yu dɔktɔ dɛm, wae no yu mɛdikal histri ɛn ɔl yu wɛl bɔdi, na di bɛst pipul dɛm fɔ no bɔt dis.

Yu tink se dɛn kin mek dɛn nɔ gɛt AML?

Nɔ, dɛn nɔ go ebul fɔ protɛkt di akyu mayloid lukimiya. Pan ɔl we masta sabi bukman dɛn no se na di jenɛtik chenj dɛn we de mek pɔsin gɛt AML, dɛn nɔ no wetin kin mek i apin. Bɔt dɛn no bɔt di tin dɛn we kin mek pɔsin gɛt AML. Na sɔm tin dɛn we kin mek yu gɛt prɔblɛm we yu kin chenj:

• Smok: Dis inklud sɛkɔn-han smok. If yu de smok, tray fɔ lɛf fɔ smok. If yu de liv ɔ wok wit pɔsin we de smok, tray fɔ stɔp di tɛm we yu de spɛn wit am we i de smok.
• Fɔ lɔng tɛm we pɔsin kin gɛt sɔm kemikal dɛn we kin mek pɔsin gɛt kansa: mɔ di bɛnzin ɛn fɔmaldehayd. If yu de wok wit dɛn tin ya we kin mek pɔsin gɛt kansa, tek ɔl di tin dɛn we yu fɔ du fɔ mek yu nɔ gɛt prɔblɛm, lɛk fɔ wɛr klos we go protɛkt yu.

Aw a kin kia fɔ misɛf? (Fɔ kia fɔ yusɛf) .

Fɔ liv wit kansa wae kin kam bak nɔr kin izi. Fɔ jɔyn kansa sɔvayv program na wan we aw yu go ebul fɔ kia fɔ yusɛf. Yu nɔ go ebul fɔ stɔp di akyu mayloid lukimiya fɔ kam bak. Bɔt yu kin du tin fɔ mek yu gɛt wɛlbɔdi as yu ebul, ilɛk wetin apin. Na sɔm advays dɛn ya:

• Akyu mayloid lukimiya tritmɛnt kin afɛkt yu it.Yu nid fɔ it fayn fɔ mek yu gɛt trɛnk. If yu gɛt prɔblɛm fɔ it, tɔk to pɔsin we sabi bɔt it.
• Di sayd ɛfɛkt dɛm we AML tritmɛnt kin gɛt kin at fɔ kɔntrol. If nid de, tɔk to yu dɔktɔ bɔt aw fɔ kia fɔ yu sik dɛn we de mek yu nɔ fil fayn.
• Kansa na tin we kin rili strɛs. Ɛksesaiz kin ɛp yu fɔ kɔntrol yu strɛs. Bɔt tɔk to yu dɔktɔ bifo yu bigin fɔ du nyu ɛksɛsayz program we go mek yu tranga.
• Kansa kin mek yu fil lɛk se na yu wangren de. AML na sik we nɔ kin apin so ɔltɛm. Yu kin fil fɔ fred fɔ tɔk bɔt yu sik. If na so i bi, tink bɔt fɔ jɔyn wan sɔpɔt grup.
• Akyu mayloid lukimiya kin mek yu fil taya bad bad wan. Di tritmɛnt dɛn kin mek yu nɔ gɛt bɛtɛ trɛnk igen. Mɛmba fɔ slip bɔku lɛk aw yu nid.

Ustɛm a fɔ go to dɔktɔ?

Yu go si yu dɔktɔ ɔltɛm ɔl di tɛm we yu de wɛl, mɔ if yu de tek mentenɛns tɛrapi. Yu dɔktɔ go tɛl yu us sayn dɛm kin bi sayn fɔ se yu AML de kam bak. Dis go ɛp yu fɔ no ustɛm fɔ kɔntakt dɛn fɔ gɛt nyu ɔ ɔda tritmɛnt.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

If yu gɛt AML, yu kin aks yusɛf dɛn kwɛstyɔn ya:

• Us kayn AML a gɛt?
• Wetin na di tritmɛnt dɛn we a kin gɛt?
• Wetin na de risk ɛn sayd ɛfɛkt wae pɔrsin kin gɛt wae pɔrsin gɛt tritmɛnt?
• Aw a go ebul fɔ kɔntrol di sayd ɛfɛkt dɛn we di tritmɛnt kin gɛt?
• Us fɔlɔp kia a nid afta tritmɛnt?
• A fɔ wach fɔ sayn dɛn we de sho se a gɛt prɔblɛm?
• Ɛni klinik trial dɛn de we a fɔ tink bɔt?

Fɔ dɔn, tin dɛn we wi fɔ mɛmba

Acute Myeloid Leukemia (AML) na wan kansa we nɔ kin apin so ɔltɛm we kin afɛkt yu bon mɛrɔ ɛn blɔd. AML kin afɛkt pipul dɛm wae dɔn pas 65 ia, bɔt i kin afɛkt pikin dɛm ɛn yɔŋ pipul dɛm bak. Tɛnki fɔ nyu tritmɛnt dɛm, mɔr pipul dɛm naw de liv wit AML in remission afta tritmɛnt. Pan ɔl we di kansa kin kam bak, di wan dɛn we de stɔdi bɔt mɛrɛsin de kɔntinyu fɔ du risach bɔt aw fɔ trit AML we kin kam bak.

If yu ɔ yu pikin gɛt akyu mayloid lukimiya, yu kin fil lɛk se dɛn dɔn trowe yu frɔm sɔlid grɔn na si we nɔ shɔ. Yu go de wɔnda if tritmɛnt go mek yu fil fayn. If na so i bi, yu go wɔri bɔt aw lɔng da rilif de go las. Yu dɔktɔ dɛn ɔndastand aw yu de fil. Dɛn go de wit yu as yu de dil wit di prɔblɛm dɛn we AML gɛt. So kɔntinyu fɔ strɔng ɛn nɔ shem fɔ gɛt di ɛp we yu nid.

` Akyu mayloid lukimiya, AML, blɔd kansa, bon mɛro, di simptom dɛm, kemotɛrapi, stem sɛl transplant